AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca’s ongoing Phase III CASPIAN study aims to evaluate the efficacy of combining durvalumab and tremelimumab with platinum-based chemotherapy for first-line treatment in patients with extensive-stage small-cell lung cancer (SCLC). The study seeks to determine if these combinations improve overall survival compared to standard chemotherapy alone.
The study tests two experimental treatments: durvalumab with tremelimumab and chemotherapy, and durvalumab with chemotherapy. These drugs are intended to enhance the immune system’s ability to fight cancer.
The study is randomized and open-label, with participants allocated to one of three treatment arms. The primary goal is to assess treatment effectiveness in extending patients’ lives.
Key dates include the study’s start on March 27, 2017, and the latest update on July 15, 2025. These dates are crucial for tracking the study’s progress and data availability.
The study’s results could significantly impact AstraZeneca’s stock, as positive outcomes may boost investor confidence and position the company favorably against competitors in the oncology market.
The CASPIAN study is ongoing, with further details available on the ClinicalTrials portal.